Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BBO-10203 |
| Trade Name | |
| Synonyms | BBO10203|BBO 10203 |
| Drug Descriptions |
BBO-10203 binds PIK3CA and disrupts the interaction with RAS, which potentially inhibits downstream signaling and decreases tumor growth (Cancer Res (2024) 84 (9_Supplement): RF02-02). |
| DrugClasses | PIK3CA inhibitor 27 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BBO-10203 | BBO-10203 | 1 | 1 |
| BBO-10203 + BBO-8520 | BBO-10203 BBO-8520 | 0 | 0 |
| BBO-10203 + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | BBO-10203 Bevacizumab Fluorouracil Leucovorin Oxaliplatin | 0 | 1 |
| BBO-10203 + Fulvestrant | BBO-10203 Fulvestrant | 0 | 0 |
| BBO-10203 + Fulvestrant + Ribociclib | BBO-10203 Fulvestrant Ribociclib | 0 | 1 |
| BBO-10203 + Palbociclib | BBO-10203 Palbociclib | 0 | 0 |
| BBO-10203 + Trastuzumab | BBO-10203 Trastuzumab | 0 | 1 |